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In vivo somatostatin receptor scintigraphy is a valuable method for the visualization of
human endocrine tumors and their metastases. In fact, peptide ligands of somatostatin
receptors (sst’s) conjugated with chelating agents are in clinical use. We have recently
developed octreotide dicarba-analogs, which show interesting binding profiles at sst’s. In
this context, it was mandatory to explore the possibility that our analogs could maintain
their activity also upon conjugation with DOTA. In this paper, we report and discuss
the synthesis, binding affinity and conformational preferences of three DOTA-conjugated
dicarba-analogs of octreotide. Interestingly, two conjugated analogs exhibited nanomolar
affinities on sst2 and sst5 somatostatin receptor subtypes.
Keywords: somatostatin receptors, dicarba-analogs, DOTA-conjugation, NMR conformational analysis,
radiotracers
INTRODUCTION
Radiolabeled peptides, targeting specific receptors of malignant cells, in primis GPCRs, have
emerged in the past years as one of the most promising tools for diagnosis and therapy
of several kinds of metastatic tumors which express these receptors (Ramogida and Orvig,
2013). Somatostatins SRIF-14 and SRIF-28 are peptide hormones, which have a wide range of
pharmacological actions on exocrine and endocrine secretions (Brazeau et al., 1973) mediated
by direct interaction with at least five GPCRs. Chemically, they are -S-S- bridged cyclic peptides
containing 14 and 28 amino acids, respectively. SRIF receptors are highly expressed in various types
of malignant cells, particularly in some neuroendocrine tumors (NETs) or neuroendocrine-like
diseases. The use of native SRIF-14, that possesses strong antisecretive and antiproliferative
properties, was hampered by the short in vivo half-life of this hormone (<3 min; Weckbecker et al.,
2003). This prompted several research groups, during the last three decades, to synthetize a huge
Abbreviations: DOTA, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid; DQF-COSY, double quantum filtered
correlated spectroscopy; DTPA, 2-[Bis[2-[bis(carboxymethyl)amino]ethyl]amino]aceticacid diethylenetriaminepentaacetic
acid; GPCRs, G protein–coupled receptors; HATU, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo
[4,5-b]pyridinium 3-oxid hexafluorophosphate, N-[(Dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-
N-methylmethanaminium hexafluoro-phosphate N-oxide; HYNIC, 6-[2-(2-sulfonatobenzaldehyde)hydrazono]nicotinyl
hydrazinonicotinic acid; NMM, 4-methylmorpholine; NOC, 1-Nal3-octreotide; NOESY, nuclear Over-hauser enhancement
spectroscopy; RCM, ring closing metathesis; SDS-d25, dodecyl-d25 sulfate sodium salt; SRIF, somatotropin release–inhibiting
factor; TATE, Tyr3-octreotate; TOC, [Tyr3]octreotide; TOCSY, total correlated spectroscopy; TSP, trimethylsilyl propionate.
Pratesi et al. Novel DOTA-Conjugated Octreotide Dicarba-Analogs
number of new size-reduced cyclic analogs with enhanced
stability in physiological conditions. Despite this synthetic effort,
only a few analogs resulted as good candidates for further
in vitro and in vivo investigations and fewer entered the
clinical practice. Among them, the cyclo-octapeptide octreotide
(Figure 1) emerged as sst2 agonist, thanks to the high affinity
and specificity toward this receptor that is over-expressed by
numerous NETs. However, the octreotide itself is a poor inhibitor
of the cell growth and it is currently used as a carrier of
radionuclides for diagnostic and therapeutic purposes. Therefore,
octreotide and its congeners like [Tyr3]-octreotide (TOC), [1-
Nal3]-octreotide (NOC) or [Tyr3, Thr8]-octreotide (TATE),
conjugated with radiolabelled chelating agents like HYNIC,
DTPA, or DOTA, gave good results when applied in imaging and
therapy of NETs (Ginj et al., 2006; Ambrosini et al., 2011; Graham
and Menda, 2011; Maecke and Reubi, 2011).
The basic parameters needed for satisfactory clinical
applications of radiolabeled SRIF analogs have been recently
pointed out by Maecke and Reubi (2011). During the last three
decades, Rivier’s group carried out an impressive work by
synthesizing a tremendous number of SRIF analogs, agonists and
antagonists, and correlating their affinity to sst1−4 receptors with
their conformation in solution (Grace et al., 2008). However,
all these synthetic cyclopeptides were bridged by S-S clasp,
mimicking the native SRIF tether, that is sensitive to enzymatic
and chemical agents. This prompted us to prepare more robust
octreotide dicarba-analogs by RCM between the allylic side
chains of two L-allylglycine (Agl) residues (Agl3 and Agl14) of
the linear peptides. The structures of octreotide (1) and of the
first dicarba-tethered analog prepared in our laboratories (2)
(Carotenuto et al., 2005) are reported in Figure 1. Despite a very
similar amino acid sequence, the affinity of 2 toward the sst2
receptor was about 70-fold less than that reported for compound
1 (D’Addona et al., 2008). No affinity improvement was detected
increasing the flexibility of 2 by double bond hydrogenation.
Later on, we prepared several other dicarba-analogs by changing
selected amino acids in the sequence of the analog 2. Some of
the novel compounds showed affinity for sst2,3,5 subtypes in
FIGURE 1 | Chemical structure of octreotide (1) and of the first dicarba-tethered analog (2). Numbering of the amino acid residues follows that of the native
SRIF.
the nM range (D’Addona et al., 2008; Di Cianni et al., 2010).
Moreover, our studies on the conformation-affinity relationship
revealed that the cyclic dicarba-analogs, having high affinity for
the sst5 subtype, showed propensity to form a 310-helix at the
C-terminal sequence (Di Cianni et al., 2010). The structures of
these compounds are reported in Figure 2.
In this paper, we describe the conjugation of the dicarba-
analogs 3a, 4a, and 5a with the DOTA chelating agent, thus
obtaining the novel cyclic peptides 3b, 4b, and 5b, which
were tested for their affinity toward sst2 and sst5 receptors.
As expected, the introduction of the DOTA moiety at the N-
terminus of the cyclic peptides affected the receptors binding
affinity of these molecules (Table 1). We here report and discuss
on the synthesis, the receptor binding affinity and conformational
preferences of these novel DOTA-conjugated octreotide dicarba-
analogs.
MATERIALS AND METHODS
General Procedures
Fmoc protected amino acids were purchased from Novabiochem
(Laufelfingen, Switzerland) and from Iris Biotech (Marktredwitz,
Germany), H-L-Thr(tBu)-ol-2-chlorotrityl resin and HATUwere
purchased from Iris Biotech. Second generation Grubbs catalyst
was obtained from Aldrich (St. Louis, MO, USA). Fmoc-Agl-
OH was purchased from Polypeptide Laboratories (Strasbourg,
France). Peptide grade DMF was from Scharlau (Barcelona,
Spain). TSP was purchased from MSD Isotopes (Montreal,
Canada). 2H2O was obtained from Aldrich. SDS-d25 was
obtained from Cambridge Isotope Laboratories, Inc. (Andover,
MA). All the other solvents and reagents used for SPPS were
of analytical quality and used without further purification. The
solid phase syntheses and DOTA-conjugations were performed
using a semi-automatic synthesizer from MultiSynTech (Witten,
Germany). Analytical RP-HPLCs were performed on a Waters
instrument equipped with a UV detector on a Phenomenex
Jupiter C18 column (5µm, 250 × 4.6 mm) using a flow rate
of 1 mL/min, with the following solvent system: 0.1% TFA in
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FIGURE 2 | Chemical structures of the studied dicarba-analogs of octreotide. Numbering of the amino acid residues follows that of the native SRIF.
TABLE 1 | Sst2,5 receptor affinities of the free and DOTA-conjugates
octreotide dicarba-analogs.
Compound Receptor (IC50, nM)
sst2 sst5
3aa 9.6 ± 0.9 16.5 ± 4.5
3b 61 ± 5.4 130 ± 7
4aa 46 ± 3 12.3 ± 0.3
4b >300 91 ± 7.8
5aa 101 ± 9 4.9 ± 1.0
5b 160 ± 8 12 ± 2.6
The mean values ± SEM were obtained on the bases of three independent repetitions of
the experiment. a Data published previously (Di Cianni et al., 2010).
H2O (A), 0.1% TFA in MeCN (B). Semi-preparative RP-HPLC
were performed on the same instrument using a flow rate of 4
ml/min with the same solvent system, on a Phenomenex Jupiter
C18 column (10µm, 250× 10mm).Mass spectra were registered
on a Thermo-Finnigan ESI LCQ Advantage mass spectrometer
(Waltham, MA, USA). LC-ESI-MS analyses were performed on
a Phenomenex Jupiter C18 column (5µm, 150 × 2.0 mm) using
a flow rate of 500µL/min on a ThermoFinnigan Surveyor HPLC
system coupled to ESI-MS, using the solvent system: 0.1% TFA in
H2O (A), 0.1% TFA in MeCN (B).
Synthesis and Purification of
Compounds 3–5
Peptides were synthesized following the method reported in
the preceding paper (Di Cianni et al., 2010). Briefly, the
peptides were prepared using the general Fmoc-SPPS strategy
on preswelled H-L-Thr(tBu)-ol-2-chloro-trityl resin. Couplings
were performed by adding 2 equivalents of protected amino acid
activated by HATU and 4 equivalents of NMM in DMF. Each
coupling was monitored by the qualitative ninhydrin (Kaiser)
test (Kaiser et al., 1970). The cyclization was performed on-
resin by second generationGrubbs catalyst (0.5mol eq. calculated
on the basis of 0.5 mmol/g of peptide). After swelling, NH2
terminal Fmoc-Agl was deprotected and coupled with Fmoc-
D-Phe-OH, affording the on-resin peptides. At this point, all
the on-resin peptides were divided in two equal amounts, one
portion was deprotected with 20% piperidine in DMF and
cleaved [3a,b with TFA/H2O/phenol (96:2:2, 3 h); 4a,b, and 5a,b
with TFA/H2O/phenol (70:28:2, 2.30 h)]. The aqueous solutions
of the peptides 3a–5a were pre-purified by solid phase extraction
and after subjected to the purification by semipreparative RP-
HPLC and subsequently characterized by ESI-MS. Analytical RP-
HPLC and ESI-MS analysis of the crude compounds revealed two
chromatographic peaks with the same MW for compounds 3a–
5a, corresponding to the geometric isomers (Z/E ratio ≈ 90:10).
Compounds were then purified by semipreparative RP-HPLC,
and the most abundant chromatographic peaks were collected.
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For all the products, HPLC purity was 97%. The other portion
with the deprotected on-resin peptides 3a–5a were coupled with
the azamacrocycle DOTA, by adding 2 equivalents of protected
DOTA-tris-tBu ester activated by 2 equivalents of HATU and 4
equivalents of NMM in DMF. Also in this case the coupling was
monitored by the Kaiser test. The crude peptides 3b–5b were
cleaved from the solid support and purified as already described.
Determination of Somatostatin Receptor
Affinity Profiles
Determination of Somatostatin receptors affinity was performed
at CEREP (Le Bois l’Evêque, B. P. 3,001, 86,600 Celle
l’Evescault, France). Cell membrane pellets were prepared from
human sst2-expressing endogeneous IMR32 cells, and sst5-
expressing human CHO cells. For each of the tested compounds,
complete displacement experiments with the universal SRIF
radio-ligand [Leu8, D-Trp22, 125I-Tyr25]-SRIF-28 (125I-[LTT]-
SRIF-28) (2000 Ci/mmol; Anawa, Wangen, Switzerland) were
performed. As control, unlabeled seglitide and SRIF-14 were
run in parallel, using the same increasing concentrations, with
sst2 and sst5 subtypes, respectively. IC50 values were calculated
by non-linear regression analysis of the competition curves
generated with mean replicate values using Hill equation curve.
The analysis was performed using software developed at CEREP
(Hill software) and validated by comparison with data generated
by the commercial software SigmaPlot 4.0 for Windows.
HPLC Estimation of Hydrophobicity
Analytical RP-HPLC was run on a Thermo Finnigan Surveyor
HPLC equipped with a Phenomenex aqua C18 column 300
Å 5µm (250 mm × 4.6 mm). The solvent systems used for
gradients were A (0.1% TFA in H2O) and B (0.1% TFA in
CH3CN). The flow rate was 1.0 mL/min, with a linear gradient
from 40 to 90% of B in 20 min. The chromatographic peaks were
monitored with a PDA detector at 254 nm.
A solution of each compound (1 mg/mL) was prepared in
HPLC-grade water and 20µL of solution were injected into the
instrument. Each compound was repeated in triplicate and the
average retention time was then calculated.
NMR Spectroscopy
The samples for NMR spectroscopy were prepared by dissolving
the appropriate amount of peptide in 0.55 mL of 1H2O (pH 5),
0.05 ml of 2H2O to obtain a concentration 1–2 mM of peptides
and 200 mM of SDS-d25. TSP was used as internal chemical
shift standard. The water signal was suppressed by gradient echo
(Hwang and Shaka, 1995). NMR experiments were recorded
on a Varian Inova-Unity 700 MHz at 308.1 K. 1D 1H NMR
spectra of the new compounds 3b–5b are reported in Figure
S1 of the Supplementary Material. Complete 1H NMR chemical
shift assignments were effectively achieved for all the analyzed
peptides (Tables S3–S5) according to the Wüthrich procedure
(Wüthrich, 1986) via the usual systematic application of TOCSY
(Braunschweiler and Ernst, 1983) and NOESY (Jeener et al.,
1979) experiments recorded in the phase-sensitive mode using
the method from States (States et al., 1982).
Typical data block sizes were 2,048 addresses in t2 and 512
equidistant t1 values. Before Fourier transformation, the time
domain data matrices were multiplied by shifted sin2 functions
in both dimensions. A mixing time of 70 ms was used for
the TOCSY experiments. NOESY experiments were run with
mixing times of 100 and 200 ms. The qualitative and quantitative
analyses of TOCSY and NOESY spectra were obtained with the
support of the XEASY software package (Bartels et al., 1995).
Structural Determinations and
Computational Modeling
The NOE-based distance restraints were obtained from NOESY
spectra collected with the mixing time of 100 ms. The
NOE cross peaks were integrated with the XEASY program
and were converted into upper distance bounds using the
CALIBA program incorporated into the program package
DYANA (Güntert et al., 1997). Only NOE derived constraints
(Tables S6–S8) were considered in the annealing procedures. In
a first calculation run, all the upper distance bounds were used,
generating an ensemble of 100 structures with the simulated
annealing standard protocol of the program DYANA. For
all peptides, a number of consistent (i.e., in all calculated
structures) violated upper limit constraints (>0.1 Å) were
observed (Tables S6–S8). These violations were discarded in a
subsequent MD run. This step was repeated until no violation
was observed (two runs were enough for all peptides). Thus, we
obtained a first family of structures (family I). In a second MD
cycle, the violated upper limit constraints of the first cycle were
up-weighted (10-fold) for the contribution to the target energy
function of DYANA. Hence, we obtained a new set of violated
constraints which were discarded in the subsequent MD runs.
After two MD runs, no violations were observed. In the final
calculation run, we applied the same weight to the not discarded
constraints and obtained a second family of structures (family II).
Since, the two sets of violations had no common member we did
not repeat further the described procedure.
Finally, 20 structures for each family of peptides 3b–5b were
chosen, whose interprotonic distances best fitted NOE derived
distances, and then refined through successive steps of restrained
and unrestrained energy minimization calculations using the
Discover algorithm (Accelrys, San Diego, CA) and the consistent
valence force field (CVFF) (Maple et al., 1988).
The minimization lowered the total energy of the structures.
The final structures were analyzed using the InsightII program
(Accelrys, San Diego, CA). Graphical representations were
carried out with the UCSF Chimera package (Pettersen
et al., 2004). The root-mean-squared-deviation analysis between
energy-minimized structures was carried out with the program
MOLMOL (Koradi et al., 1996).
RESULTS AND DISCUSSION
Peptide Synthesis and Purification
The synthesis of dicarba-analogs followed the procedure
described in our previous article (Di Cianni et al., 2010). All the
syntheses take advantages from the Solid Phase Peptide Synthesis
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protocol, allowing to rapidly afford the products in the range
from aµM to mM scale and with high purity level.
The syntheses of the linear peptides were performed on a
2-chloro-trityl resin pre-loaded with the protected aminoalcool
H-L-Thr(tBu)-ol and following the Scheme 1. The peptide chain
elongation, according to the selected amino acid sequence, was
achieved by the coupling of a pre-activated Fmoc-protected
amino acid with HATU and NMM. All the couplings were
checked by the Kaiser test (Kaiser et al., 1970). Once the syntheses
of the linear peptides were completed, the corresponding
dicarba-cyclopeptides were obtained by RCM reactions catalyzed
with the second generation Grubb’s catalyst in anhydrous DCM
for 48 h at 50◦C.
At this point, the last amino acid residue D-Phe, was coupled
to the three on-resin cyclopeptides and the resins were divided
in two halves. One of these was cleaved in order to obtain
the free dicarba-cyclopeptide 3a–5a, while the other underwent
to the DOTA coupling on the free amino-group of the D-Phe
residue with the DOTA-tris-tBu ester, suitably activated with
HATU and NMM. Also in this case, the compounds were cleaved
from the solid support, affording the crude products 3b–5b. The
cleavage of compounds 3a,b was carried out with a mixture of
TFA/H2O/phenol (96:2:2) for 3 h at r.t., while compounds 4a,b,
and 5a,b, that needed some milder conditions since the OBz
must be retained on the side-chain of the Tyr residue, were
treated with TFA/H2O/phenol (70:28:2) for 2.5 h. All compounds
obtained were pre-purified by SPE. The concentrated solutions
of the raw products were adsorbed on the SPE and eluted with
an increased percentage of CH3CN in H2O (from 0 to 100%).
The enriched fractions were then purified by semipreparative
RP-HPLC and characterized by ESI-MS (see Tables S1, S2).
For each peptide, the HPLC chromatogram showed two peaks
with the same MW, corresponding to the geometric isomers
(Z/E ratio ≈ 90:10). In particular, the Z structure of the C-
C = C-C tether of the sample, eluted at higher Rt , was recovered
and the cis-structure ascertained by 1H NMR inspection. In
particular, the geometry of the double bond of compounds
3b–5b was confirmed as cis (E) from the coupling constant value
(3JCH=CH = 11 Hz) between the two olefinic protons of the
bridge (Figure S2) and the relative strong NOE between the same
olefinic Hγs. Since, the signals of the two olefinic protons of all
compounds 3b–5b overlapped each other in the NMR spectra
acquired in SDS solutions, previous parameters were extracted
from spectra acquired in D2O solution. The HPLC purity of each
compound was >97%, and the isolated structure showed unique
Z configuration, confirmed by NMR analysis. No oligomeric
by-products were observed.
Binding Affinity to sst2,5 Receptors
The three DOTA conjugated compounds 3b, 4b, and 5b were
tested for their ability to bind to the sst2 and sst5 receptors
subtypes in complete displacement experiments using the
SCHEME 1 | Synthetic route to compounds 3a-5a and 3b-5b.
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universal somatostatin radioligand [125I]-[Leu8,D-Trp22,Tyr25]-
somatostatin-28. IC50 values were calculated after quantification
of the data using a computer-assisted image processing system
(Table 1). Receptor subtypes sst2 and sst5 were chosen for
preliminary binding assays because of their overexpression in
some tumor types (Miller et al., 1995). In Table 1, the affinities
of the parent unconjugated compounds 3a, 4a, and 5a are also
reported for comparison (Di Cianni et al., 2010).
Bearing in mind that affinity values >100 nM cannot permit
to consider the related compounds of pharmacological interest,
from data reported in Table 1 it clearly appears that 3bmaintains
a fairly good affinity for sst2 while it loses affinity for sst5 subtype.
The opposite case is reported for the Tyr(OBz)10 containing
derivative 4b that shows a moderate reduction of the affinity at
the sst5 receptor but a total loss of sst2 affinity. In the case of
compound 5b, after the conjugation with DOTA there is roughly
no effect on sst2 activity while the sst5 affinity is reduced (2.4-
fold). Nevertheless, the binding ability with sst5 still remains of
significant interest.
HPLC Estimation of Hydrophobicity
RP-HPLC retention time (tR) measurements can give an idea
of the difference in hydrophobicity of our peptides after the
conjugation with DOTA (Table 2; Tachi et al., 2002; Hossain
et al., 2011).
Compound 3a is, as expected, the less hydrophobic analog
having the –OH group of the Thr10 side chain in the place of
the lipophilic Tyr(OBz)10 residue of 4a and 5a. On the other
hand, it is not surprisingly that 5a is still more hydrophobic
than 4a because of the outcome of the aromatic naphtyl side
chain in position 7. The introduction of the DOTA moiety at the
amino end of these analogs enhanced the affinity of the entire
molecule for the stationary phase through a slight increment of
the chromatographic retention times, at least in our experimental
conditions but did not alter the hydrophobic/hydrophilic nature
of the molecules to any significant extent. Noticeably, the
contribution to the hydrophobicity carried by the DOTA moiety
is almost the same for 3b–5bmolecules. Because the lipophilicity
= hydrophobicity—polarity (Giaginis and Tsantili-Kakoulidou,
2008), these finds seem to suggest that changes in hydrophobicity
and then also in lipophilicity, introduced by the conjugation with
the DOTA group, show a very similar trend along the three
structures.
TABLE 2 | RP-HPLC comparison of retention time of dicarba-analogs and
their respective DOTA-conjugated analogs.
Compound TR (MIN) 1 TR (MIN)
3a 6.14 0.65
3b 6.79
4a 10.39 0.55
4b 10.94
5a 12.02 0.55
5b 12.57
NMR Analysis
NMR analysis of the analogs 3b–5b was performed in SDS-d25
micelles solution. The employment of SDS micelles to investigate
the conformational properties is justified on the basis of their
interaction with a membrane receptor. For peptides that bind
membrane receptors, such as GPCR, the use of membrane
mimetic solution is suggested, hypothesizing a membrane-
assisted mechanism of interactions between the peptides and
their receptors (Sargent and Schwyzer, 1986). Hence micelle
solutions have been extensively used for conformational studies
of peptide hormones and neuropeptides (Grieco et al., 2011;
Carotenuto et al., 2013, 2015).
For compound 3b, NMR data resemble those of the
corresponding parent 3a (Table S3) with the main differences
located at N-terminal residues 2-3-7 (Note: numbering of
the residues follows that of native SRIF, Figure 2). As for
3a (Di Cianni et al., 2010), NOESY spectra of 3b showed,
simultaneously, both diagnostic connectivities consistent with
folded structures and NOE contacts characteristic of extended
regions (Table S6). Considering incompatible NOEs separately in
different calculation cycles (Di Cianni et al., 2010), two families
of conformation were obtained (Figure 3); family I with a type
II’ β-turn spanning residues D-Trp8-Lys9, followed by a short
310-helix along residues 10-14-15 (Figure 3A) and family II
which differed from the first mainly in that C-terminal residues
were in extended conformations (Figure 3B). Compared to the
conformations obtained for peptide 3a, the principal difference
in both families is a better definition of D-Phe2 side chain
which is predominately gauche- oriented in 3b, and a higher
conformational freedom for 1-Nal7 side chain which populates
both trans and gauche- conformers starting (in 3a) from a
preferred trans conformation. D-Phe2 reorientation is probably
due to attractive interactions between D-Phe andDOTAmoieties,
while 1-Nal7 movements should be a consequence of the first.
Interactions between D-Phe2 residue and N-terminal conjugate
moieties were already observed in other octreotide dicarba-
derivatives (Barragán et al., 2012).
These conformational modifications have to account for the
loss of activity at receptors, mainly at the subtype sst5, because
probably the reorientation of the 1-Nal7 induces the loss of
an important interaction. Differently from NMR spectra of
3a, those of Tyr(OBz) containing compounds (4b, and 5b)
show significant differences regarding all residues compared
to the parents 4a and 5a, respectively (Tables S4, S5). Some
NOE interactions between Tyr(OBz) side chain and both Phe7
(1-Nal7) and D-Trp8 could be observed (Tables S7–S8). Structure
calculation explained the experimental NMR data. In fact,
apart the gauche- side chain orientations of D-Phe2 and of
Phe7 (1-Nal7) already described for 3b, Tyr(OBz) side chain
of both extended (family I) and folded (family II) structure
clusters of 4b and 5b had a gauche+ orientation (Figures 4, 5).
Henceforth, the long Tyr(OBz) side chain is inserted between
the aromatic systems of Phe7 (1-Nal7) and D-Trp8. This tight
packing blocks the rotation of both Phe7 (1-Nal7) and D-
Trp8. As a consequence of this loss of rotational freedom
D-Trp8 indole moiety is closer, on average, to Lys9 residue
compared to what happens in the unconjugated peptides;
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FIGURE 3 | Superposition of the 10 lowest energy conformers of 3b: family I (A), family II (B). Structure models were superimposed using the backbone
heavy atoms. Lowest energy conformer is evidenced with thicker stick and different colors of the backbone atoms (carbon, green; nitrogen, blue; oxygen, red; sulfur,
yellow). DOTA position is showed as a black ball. Hydrogen atoms of the side chains are hidden for a better view.
FIGURE 4 | Superposition of the 10 lowest energy conformers of 4b: family I (A), family II (B). Structure models were superimposed using the backbone
heavy atoms. Lowest energy conformer is evidenced with thicker stick and different colors of the backbone atoms (carbon, green; nitrogen, blue; oxygen, red; sulfur,
yellow). DOTA position is showed as a black ball. Hydrogen atoms of the side chains are hidden for a better view.
this is in accordance with the significant upfield shifts of
all the proton signals of Lys9. This compact conformation
is favorable to the sst5 binding of 5b (and partially of
4b) since this compound recovers the affinity toward sst5
compared to 3b.
At the same time, 4b and 5b show amoderate/slight reduction
of the affinity toward sst5 compared to 4a and 5a, respectively,
again the non-perfect orientation of Phe7 (1-Nal7) can explain
this worsening. Considering the sst2 receptor, a slight (5b) or total
loss (4b) of affinity is observed. Unfortunately, due to their poor
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FIGURE 5 | Superposition of the 10 lowest energy conformers of 5b: family I (A),family II (B). Structure models were superimposed using the backbone heavy
atoms. Lowest energy conformer is evidenced with thicker stick and different colors of the backbone atoms (carbon, green; nitrogen, blue; oxygen, red; sulfur, yellow).
DOTA position is showed as a black ball. Hydrogen atoms of the side chains are hidden for a better view.
overall affinities for sst2 (both >100 nM), neither compound,
4b or 5b, can be considered as a good candidate for eliciting
pharmacological activity on this receptor subtype. Consequently,
the “cross-arm” orientation of Tyr(OBz) in the context of the β-
hairpin structure (Figures 4B, 5B), that is considered the binding
conformer at the sst2 (Grace et al., 2006), results to be not suitable
for sst2 receptor.
CONCLUSION
In summary, we have prepared three novel DOTA conjugated
peptides, which derive from previously developed cyclic dicarba-
analogs 3a, 4a, and 5a with low nanomolar affinity toward
somatostatin receptors. The new cyclic peptides 3b, 4b, and
5b were tested for their affinity toward sst2 and sst5 receptors.
Compounds 3b and 5b maintained moderate to high affinities
of their unconjugated parents for the sst2 and sst5 receptors,
respectively. Detailed conformational analysis by solution NMR
revealed the possible reasons behind the observed affinity
profiles. These very encouraging results will prompt us to load
the developed conjugated peptides with different radiometals and
to test the novel radiotracers both for diagnostic and therapeutic
aims.
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